Options Edge: American Express, Genzyme, Baidu, and Research In Motion Limited

The credit card concern expands its Internet presence with a key acquisition

by Elizabeth Harrow (eharrow@sir-inc.com) 11/18/2009 9:29 AM


Today's column includes merger-and-acquisition news from American Express Company (AXP), disappointing drug news from Genzyme Corporation (GENZ), a more cautiously bullish outlook for Baidu, Inc. (BIDU), and a downbeat brokerage note for Research In Motion Limited (RIMM). Each day, Options Edge focuses on the hot stocks in the news and gives you a unique insight into each stock's sentiment backdrop. Our time-tested contrarian approach centers on options, and gives you the trading tools to approach the day with a much-needed edge over the investing herd.

American Express Company

American Express Company (AXP: View sentiment for AXPsentiment, chart, options) announced this morning that it agreed to acquire Revolution Money, an Internet-based payment platform, for $300 million. The buyout is expected to close during the first quarter of 2010, pending regulatory review. Jason Hogg will stay on board as Revolution Money's president and CEO.

AXP price chart"New payments products and platforms are evolving rapidly, and it's important for us to keep identifying cutting-edge technologies that can extend our leadership beyond the traditional payments arena," explained Kenneth Chenault, AXP's chairman and CEO. "While Revolution Money is a young and relatively small company, we believe it has big potential. This is a smart, nimble business."

AXP is little changed in pre-market trading, but the stock has racked up an impressive year-to-date gain of 123%. The shares recently accelerated higher, and they're now hovering several points beyond support from their 10-week and 20-week moving averages.

Despite AXP's stellar price action in 2009, call players have relatively modest expectations for the equity. In the November series, which is due to expire on Friday, peak call open interest of 11,714 contracts lies at the in-the-money 38 strike.

Genzyme Corporation

Genzyme Corporation (GENZ: View sentiment for GENZsentiment, chart, options) said today it will cease development on its experimental advanced phosphate binder, because the drug did not show a significant improvement over the company's existing drug, Renvela, in a phase II/III trial. Both preparations are meant to treat a condition known as hyperphosphatemia, which can occur in patients with chronic kidney diseases.

GENZ is down 1.1% ahead of the bell, with the shares continuing their long-term trek south beneath pressure from their 10-month moving average. This trendline hasn't been toppled on a monthly closing basis since September 2008.

Speculative investors seem undeterred by GENZ's lackluster performance on the charts, with calls dominating the equity's near-term open interest. The stock's Schaeffer's put/call open interest ratio (SOIR) checks in at 0.41, which ranks within four percentage points of an annual optimistic peak.

Today's Most Popular Stories




Featured Companies





Receive FREE access to Schaeffer’s
Sentiment Spring 2009
premier online options magazine!



Partner Center

tribal fussion